Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today

We deliver Mobile Wallet Market Research and SWOT Analysis from Alternative Energy to Pharmaceuticals and Healthcare Market Research Reports to Digital Media.

Skip to Main Content »

Search Site
Researchers Currently Online:494

Search results for 'pipeline drugs'

  1. 
Pipeline Insight: Depression - Novel drugs to grow third-line market

    Pipeline Insight: Depression - Novel drugs to grow third-line market

    Date of report : Mar 22, 2007
    $11,400.00

    Introduction Datamonitor believes that companies developing pipeline drugs for the depression market should concentrate resources on targeting third-line depression patients, a market with significant sales volume and few viable treatment options. GSK’s gepirone ER is likely to be the first pipel...  Learn More
  2. 
Pipeline Insight: Osteoporosis - Bone building drugs become the heart of the pipeline

    Pipeline Insight: Osteoporosis - Bone building drugs become the heart of the pipeline

    Date of report : Jan 6, 2010
    $11,400.00

    Introduction Osteoporosis continues to be an attractive therapy area for large pharmaceutical companies due to its high prevalence rate and unmet need. Across the seven major markets, sales for osteoporosis drugs grew with a compound annual growth rate (CAGR) of 2.0% from 2005 to $6.9 billion in 20...  Learn More
  3. 
Pipeline Insight: Multiple Sclerosis - Risk-benefit ratio under the spotlight for potent pipeline drugs

    Pipeline Insight: Multiple Sclerosis - Risk-benefit ratio under the spotlight for potent pipeline drugs

    Date of report : Dec 17, 2009
    $11,400.00

    Introduction Sales of multiple sclerosis disease-modifying therapies exceeded $6.0 billion in 2008 across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK). Datamonitor anticipates the combination of continuing strong historical growth dynamics and the uptake of the firs...  Learn More
  4. Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share

    Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share

    Date of report : Jan 11, 2012
    $3,500.00

    Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share Summary GBI Research, the leading business intelligence provider, has released its latest research “Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain B...  Learn More
  5. 
Pipeline Insight: Neuropathic Pain - Emerging drugs fail to capitalize in lucrative market

    Pipeline Insight: Neuropathic Pain - Emerging drugs fail to capitalize in lucrative market

    Date of report : Sep 26, 2007
    $11,400.00

    Introduction The neuropathic pain market is forecast to double from 2006 to reach over $7 billion by 2016. At this time, the current late-stage neuropathic pain pipeline is forecast to take only 18% of the total market share, highlighting an opportunity for better pipeline drugs that demonstrate im...  Learn More
  6. 
Forecast Insight: Neuropathic Pain - Brighter future for pipeline drugs while current brands downgraded

    Forecast Insight: Neuropathic Pain - Brighter future for pipeline drugs while current brands downgraded

    Date of report : Apr 12, 2009
    $15,200.00

    Introduction Datamonitor forecasts the neuropathic pain market to more than double in value from 2008 to total $5.2 billion by 2018 across the seven major markets (US, Japan, and the 5EU [France, Germany, Italy, Spain and the UK]). Although the US will provide the greatest increase in value over th...  Learn More
  7. 
Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types

    Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types

    Date of report : Jun 20, 2011
    $11,400.00

    Introduction In 2008, the six tumor types covered in this report are forecast to account for over 1.2m new cases of cancer. Collectively, the 36 different drugs in Phase III development for the six tumor types are forecast to achieve $7,049m in sales by 2017. This constitutes a significant proporti...  Learn More
  8. 
Stakeholder Opinions: Small Cell Lung Cancer and Malignant Mesothelioma -  Limited R&D activity provides opportunity for early-phase pipeline drugs

    Stakeholder Opinions: Small Cell Lung Cancer and Malignant Mesothelioma - Limited R&D activity provides opportunity for early-phase pipeline drugs

    Date of report : Mar 13, 2007
    $3,800.00

    Introduction SCLC accounts for one-fifth of all lung tumor types. More than 80,000 new cases are expected to be diagnosed in 2007 in the seven major markets, although it is set to decrease due to changing smoking habits. Mesothelioma is rarer, although incidence is expected to increase in the comin...  Learn More
LiveZilla Live Help